Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Alzheimer’s Disease

Bill Gates Investing $50 Million to Help Alzheimer’s Research — And It’s Personal

Bill Gates

Seattle, WA, November 16, 2017 — Lindsey Bever reports in The Washington Post that Bill Gates is personally investing $50 million to help fund research to find a treatment for Alzheimer’s disease, a type of dementia Gates says has struck members of his own family.

There is no cure for Alzheimer’s, which destroys memory and other mental processes, so Gates said he is investing his own money in the Dementia Discovery Fund, a private-public partnership to search for a solution.

“It’s a terrible disease that devastates both those who have it and their loved ones,” the philanthropist wrote on November 13 on his blog. Continue reading

National Institute on Aging Report: Promising But Inconclusive Evidence on Interventions to Prevent Cognitive Decline, Dementia

Bethesda, MD, June 23, 2017 — The public is enormously concerned about dementia and cognitive impairment, and a wide range of programs and products, such as diets, exercise regimens, games, and supplements, purport to keep these conditions at bay.

It is difficult for individuals, health care providers and policy makers to ascertain what has been demonstrated to prevent or reduce risk.

To help sort through the data and to understand the quality and weight of current evidence for possible interventions, the National Institute on Aging (NIA) at the National Institutes of Health (NIH), commissioned experts for an extensive scientific review and to provide recommendations for public health messaging and future research priorities. Continue reading

Rowan/Rutgers Board Teams Up with Otsuka America Pharmaceuticals to Improve Alzheimer’s Care Model

Camden, NJ, May 13, 2017 — Anjalee Khemlani reports in NJBIZ that a new public-private partnership between the Rowan University/Rutgers-Camden Board of Governors and Otsuka America Pharmaceuticals Inc. in Princeton aims to create a better care model for patients with Alzheimer’s — a disease that adversely affects a significant portion of Camden’s residents.

Being touted as the first of the kind in the nation, the new program is based off a model Otsuka used for oncology with the University of Alabama at Birmingham.

The results of the program were revealed in a report from Otsuka released Tuesday during the announcement of the new project in Camden. Continue reading

Alzheimer’s Association and Alzheimer’s Impact Movement Lead the Way to $400 Million Federal Research Increase

Washington, DC, May 9, 2017 — The Alzheimer’s Association, the Alzheimer’s Impact Movement (AIM) and its nationwide network of advocates applaud Congress for hearing their call and taking action in the fight to end Alzheimer’s.

On May 5, a $400 million increase in Alzheimer’s research funding was signed into law, increasing federal funding at the National Institutes of Health (NIH) to nearly $1.4 billion.

After years of stagnant funding, this is the second year in a row the Alzheimer’s Association request for historic funding increases has been acted on by our federal leaders. Continue reading

Congress Boosts Research Funding in Cancer, Alzheimer’s, Precision Medicine, BRAIN Initiative and ‘Superbugs’

Washington, DC, May 2, 2017 — Ariana Eunjung Cha reports in The Washington Post that Congress unveiled a bipartisan budget late Sunday that contains a number of welcome surprises for researchers who had been panicking since March, when President Trump proposed deep funding cuts for science and health.

Under the deal, the National Institutes of Health will get a $2 billion boost in fiscal year 2017, as it did the previous year.

Trump had proposed cutting the NIH budget by about one-fifth, or $6 billion, in a draft 2018 budget.

Here are some of the big research winners: Continue reading

Rutgers Research: Chemical Used to Detect Sticky Buildup in Brains of Alzheimer’s Victims Extends Roundworm Lifespan

New Brunswick, NJ, March 10, 2017 — Robin Lally reports that while many anti-aging drugs don’t live up to their claim, a tightly replicated study by Rutgers and a group of researchers from around the country discovered that a chemical used to detect amyloid plaques found in the brains of those with Alzheimer’s extended the lifespan of thousands of roundworms similar in molecular form, function and genetics to humans.

In a study involving more than 44,000 animals published in Nature Communications, researchers from Rutgers, The University of Oregon, and the Buck Institute for Research on Aging in California tested 10 different compounds from multiple species of roundworms that featured more genetic diversity than can be found between mice and humans. Continue reading

Rutgers Study: Alzheimer’s May Be Linked to Defective Brain Cells Spreading Disease

New Brunswick, NJ, February 16, 2017 — Robin Lally reports for Rutgers Today that university scientists say neurodegenerative diseases like Alzheimer’s and Parkinson’s may be linked to defective brain cells disposing toxic proteins that make neighboring cells sick.

In a study published in Nature, Monica Driscoll, distinguished professor of molecular biology and biochemistry, School of Arts and Sciences, and her team, found that while healthy neurons should be able to sort out and rid brain cells of toxic proteins and damaged cell structures without causing problems, laboratory findings indicate that it does not always occur. Continue reading

Rutgers Research: New Molecular Discovery May Help Identify Drug Therapies to Treat Dementia

Alzheimer's WordsNew Brunswick, NJ, January 30, 2017 — Robin Lally reports that Rutgers University scientists have discovered a molecular pathway in the brain that may help provide answers to long-term memory problems in the elderly and aid researchers in identifying drug-based therapies to prevent dementia.

“Memory decline brings much suffering to the affected individuals and their families and leads to staggering social and economic costs,” said Gleb Shumyatsky, an associate professor in the Department of Genetics in the School of Arts and Sciences, who co-authored the study with former postdoctoral researcher Shusaku Uchida. Continue reading

Alzheimer’s New Jersey Makes Its Way After Split from National Group

Alzheimer's New Jersey logoDenville, NJ, January 20, 2017 — Anajalee Khamlani reports on NJBIZ that, after completely rebranding and disassociating from the national Alzheimer’s Association, the 1-year-old Alzheimer’s New Jersey is standing on fairly stable ground.

There were some hiccups, such as donors being confused by the Greater New Jersey Alzheimer’s Association chapter and Alzheimer’s New Jersey’s new brand, as well as similar schedules for events and walks, but overall, things went smoothly, said CEO and President Kenneth Zaentz.

“We are definitely on track for what we want to accomplish,” he said. Continue reading

Congress Passes 21st Century Cures Act; President Obama Praises Bill to Accelerate Medical Innovation

21st-century-cures-blueWashington, DC, December 8, 2016 — Mike DeBonis reports in The Washington Post that Congress passed sweeping legislation yesterday that boosts funding for medical research, eases the development and approval of experimental treatments and reforms federal policy on mental health care.

The 94 to 5 Senate vote Wednesday followed a 392 to 26 House vote last week.

The bill, known as the 21st Century Cures Act, now heads to the desk of President Obama, who praised the bill Wednesday and said he would sign it. Continue reading